Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

Susan M. Landau; Danielle J Harvey; Cindee M. Madison; Robert A. Koeppe; Eric M. Reiman; Norman L. Foster; Michael W. Weiner; William J. Jagust

doi:10.1016/j.neurobiolaging.2009.07.002

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

Susan M. Landau, Danielle J Harvey, Cindee M. Madison, Robert A. Koeppe, Eric M. Reiman, Norman L. Foster, Michael W. Weiner, William J. Jagust

Public Health Sciences

Research output: Contribution to journal › Article

370 Scopus citations

Abstract

The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.

Original language	English (US)
Pages (from-to)	1207-1218
Number of pages	12
Journal	Neurobiology of Aging
Volume	32
Issue number	7
DOIs	https://doi.org/10.1016/j.neurobiolaging.2009.07.002
State	Published - Jul 2011

Keywords

Alzheimer's disease
FDG-PET
Mild cognitive impairment

ASJC Scopus subject areas

Clinical Neurology
Neuroscience(all)
Aging
Developmental Biology
Geriatrics and Gerontology

Access to Document

10.1016/j.neurobiolaging.2009.07.002

Fingerprint Dive into the research topics of 'Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI'. Together they form a unique fingerprint.

Cite this

Landau, S. M., Harvey, D. J., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011). Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging, 32(7), 1207-1218. https://doi.org/10.1016/j.neurobiolaging.2009.07.002

@article{47209ca0af054c67a8321ca5ec45cf7d,

title = "Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI",

abstract = "The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.",

keywords = "Alzheimer's disease, FDG-PET, Mild cognitive impairment",

author = "Landau, {Susan M.} and Harvey, {Danielle J} and Madison, {Cindee M.} and Koeppe, {Robert A.} and Reiman, {Eric M.} and Foster, {Norman L.} and Weiner, {Michael W.} and Jagust, {William J.}",

year = "2011",

month = jul,

doi = "10.1016/j.neurobiolaging.2009.07.002",

language = "English (US)",

volume = "32",

pages = "1207--1218",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

AU - Landau, Susan M.

AU - Harvey, Danielle J

AU - Madison, Cindee M.

AU - Koeppe, Robert A.

AU - Reiman, Eric M.

AU - Foster, Norman L.

AU - Weiner, Michael W.

AU - Jagust, William J.

PY - 2011/7

Y1 - 2011/7

N2 - The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.

AB - The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.

KW - Alzheimer's disease

KW - FDG-PET

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=79958766587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958766587&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2009.07.002

DO - 10.1016/j.neurobiolaging.2009.07.002

M3 - Article

C2 - 19660834

AN - SCOPUS:79958766587

VL - 32

SP - 1207

EP - 1218

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 7

ER -